drugset
drugset / Trial / NCT01730586

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

NCT01730586 ↗

Phase 2 Completed 34 enrolled M.D. Anderson Cancer Center Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied. Abraxane is designed to block cancer cells from dividing, which may cause them to die.

Timeline

Start
2012-11
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Abraxane Small molecule 220 mg/m2 Intravenous

Indications

colorectal cancer